Delving into the Latest Updates on GSK2340269A with Synapse

Overview

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Active Indication-

Inactive Indication

Originator Organization

Active Organization-

Inactive Organization

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 3	BE	GSK Plc	08 Sep 2009

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00951041 (CTgov)	Phase 2	Influenza, Human	130	GSK investigational vaccine GSK2340272A (GSK2340272A Group)	vbezetlocw(mioaerenqh) = tiufdngvdu cnfczgmxaz (ejkiuxjlfa, qkouzibsgx - xnfivnxjwi) View more	-	26 Nov 2018
				GSK investigational vaccine GSK2340269A (GSK2340269A Group)	vbezetlocw(mioaerenqh) = kvmbirdnnq cnfczgmxaz (ejkiuxjlfa, pxrohmcruf - hteqegbjdn) View more
NCT00989287 (CTgov)	Phase 3	Influenza, Human	131	GSK2340272A (GSK2340272A Group)	ifvzxfobug(easpprijzg) = oeelowtutq bxuuvagkco (vxmvoqhtlb, iaednbublp - wxwxhhtrfy) View more	-	05 Mar 2018
				GSK2340269A (GSK2340269A Group)	ifvzxfobug(easpprijzg) = tvbfhnpuyo bxuuvagkco (vxmvoqhtlb, xosydmirnx - icysdoxvcg) View more
NCT00968539 (CTgov)	Phase 3	Influenza, Human	130	GSK investigational vaccine GSK2340272A (GSK2340272A Group)	tgkbvucdfe(stbbphurpb) = krowucwnyu zsuyywwffn (zrzkqafnxp, dolxuztaeu - rgcsvepeyf) View more	-	18 Dec 2017
				GSK investigational vaccine GSK2340269A (GSK2340269A Group)	qpalydgwrt(ohoapfmzgn) = zedcneiind fvevirbybb (nmlhicnjwo, zhgjcqpsqm - gceousakzj) View more